Background: anti-tumour necrosis factor-α (anti-TNF) therapy use has risen in paediatric-onset inflammatory bowel disease (PIBD). Whether this has translated into preventing/delaying childhood surgery is uncertain. The Wessex PIBD cohort were analysed for trends in anti-TNF-therapy and surgery. Design: all patients diagnosed with PIBD within Wessex from 1997-2017 were assessed. Prevalence of anti-TNF-therapy and yearly surgery rates (resection and perianal) during childhood (<18 years) were analysed (Pearson’s correlation, multivariate regression, Fisher’s exact). Results: eight-hundred-and-twenty-five children were included (498 Crohn’s disease, 272 ulcerative colitis, 55 IBD-unclassified), mean age at diagnosis 13.6 years (1.6-17.6),...
Background: Accelerated step-up or anti-tumor necrosis factor (TNF) before first remission is curren...
BACKGROUND: Accelerated step-up or anti-tumor necrosis factor (TNF) before first remission is curren...
© 2018 AGA Institute Background & Aims: Up to 30% of patients with Crohn\u27s disease (CD) require s...
International audienceObjectives: We evaluated the impact of immunosuppressants (IS) and anti-tumor ...
International audienceObjectives: We evaluated the impact of immunosuppressants (IS) and anti-tumor ...
International audienceObjectives: We evaluated the impact of immunosuppressants (IS) and anti-tumor ...
BACKGROUND & AIMS: Up to 30% of patients with Crohn\u27s disease (CD) require surgery within the fir...
BACKGROUND & AIMS: Up to 30% of patients with Crohn\u27s disease (CD) require surgery within the fir...
BACKGROUND & AIMS: Up to 30% of patients with Crohn\u27s disease (CD) require surgery within the fir...
BACKGROUND & AIMS: Up to 30% of patients with Crohn\u27s disease (CD) require surgery within the fir...
BACKGROUND & AIMS: Up to 30% of patients with Crohn\u27s disease (CD) require surgery within the fir...
International audienceBackground: Anti-TNF agents are the first biologic treatment option in inflamm...
Background: Accelerated step-up or anti-tumor necrosis factor (TNF) before first remission is curren...
Background: Accelerated step-up or anti-tumor necrosis factor (TNF) before first remission is curren...
International audienceBackground: Anti-TNF agents are the first biologic treatment option in inflamm...
Background: Accelerated step-up or anti-tumor necrosis factor (TNF) before first remission is curren...
BACKGROUND: Accelerated step-up or anti-tumor necrosis factor (TNF) before first remission is curren...
© 2018 AGA Institute Background & Aims: Up to 30% of patients with Crohn\u27s disease (CD) require s...
International audienceObjectives: We evaluated the impact of immunosuppressants (IS) and anti-tumor ...
International audienceObjectives: We evaluated the impact of immunosuppressants (IS) and anti-tumor ...
International audienceObjectives: We evaluated the impact of immunosuppressants (IS) and anti-tumor ...
BACKGROUND & AIMS: Up to 30% of patients with Crohn\u27s disease (CD) require surgery within the fir...
BACKGROUND & AIMS: Up to 30% of patients with Crohn\u27s disease (CD) require surgery within the fir...
BACKGROUND & AIMS: Up to 30% of patients with Crohn\u27s disease (CD) require surgery within the fir...
BACKGROUND & AIMS: Up to 30% of patients with Crohn\u27s disease (CD) require surgery within the fir...
BACKGROUND & AIMS: Up to 30% of patients with Crohn\u27s disease (CD) require surgery within the fir...
International audienceBackground: Anti-TNF agents are the first biologic treatment option in inflamm...
Background: Accelerated step-up or anti-tumor necrosis factor (TNF) before first remission is curren...
Background: Accelerated step-up or anti-tumor necrosis factor (TNF) before first remission is curren...
International audienceBackground: Anti-TNF agents are the first biologic treatment option in inflamm...
Background: Accelerated step-up or anti-tumor necrosis factor (TNF) before first remission is curren...
BACKGROUND: Accelerated step-up or anti-tumor necrosis factor (TNF) before first remission is curren...
© 2018 AGA Institute Background & Aims: Up to 30% of patients with Crohn\u27s disease (CD) require s...